- Home
- CVM
as 07-26-2024 4:00pm EST
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | VIENNA |
| Market Cap: | 66.6M | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $3.23 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3413.33% |
Stock Insider Trading Activity of Cel-Sci Corporation (CVM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watson Robert Eugene | CVM | Director | May 8 '24 | Buy | $1.39 | 20,000 | $27,800.00 | 24,431 | SEC Form 4 |
| PRICHEP PATRICIA B | CVM | Senior Vice President | May 8 '24 | Buy | $1.39 | 8,000 | $11,120.00 | 232,326 | SEC Form 4 |
| KERSTEN GEERT R | CVM | Chief Executive Officer | May 8 '24 | Buy | $1.39 | 30,000 | $41,700.00 | 1,195,309 | SEC Form 4 |
Latest Cel-Sci Corporation News
CVM Breaking Stock News: Dive into CVM Ticker-Specific Updates for Smart Investing
MT Newswires
8 hours ago
Cel-Sci Prices $10.8 Million Offering
Business Wire
8 hours ago
CEL-SCI Announces Pricing of $10.8 Million Offering
Business Wire
12 hours ago
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
MT Newswires
18 days ago
Cel-Sci Appoints Robert Watson Board's Chair
Business Wire
18 days ago
CEL-SCI Appoints Robert Watson as Chairperson of the Board
Business Wire
a month ago
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Compare CVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.